Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.55 |
| ▸ | IGF1R | P08069 | 4/20 | 0.55 |
| ▸ | FLT4 | P35916 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | ICMT | O60725 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7308490 | 0.91 | EGFR (0.61) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7314584 | 0.90 | EGFR (0.52) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7315166 | 0.90 | EGFR (0.64) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7318677 | 0.89 | EGFR (0.55) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7310034 | 0.87 | EGFR (0.54) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7305494 | 0.86 | EGFR (0.51) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7318188 | 0.85 | EGFR (0.57) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7317891 | 0.85 | EGFR (0.49) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7316830 | 0.84 | EGFR (0.52) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7311824 | 0.84 | EGFR (0.56) | EGFRIGF1RFLT4KDRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | claimed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | EGFR 4683/4885IGF1R 4834/4885FLT4 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.